Value is emerging in the CSL Limited (ASX: CSL) share price even though it has largely gone nowhere in the last 12 months.
However, that might be about to change after Macquarie Group Ltd (ASX: MQG) upgraded the blood products biotech to “outperform” from “neutral”.
The move has yet to make much difference to the CSL share price. It’s trading just under breakeven at $314.64 during lunch time trade.
It’s pretty much the same story for the S&P/ASX 200 Index (Index:^AXJO), which just slipped into negative territory.
Outlook improving for the CSL share price
Coming back to CSL, the analysts at Macquarie believe the headwinds that have held back its shares are easing.
The first headwind comes from rivals who are pioneering new treatment options for myasthenia gravis (MG) and idiopathic thrombocytopenic purpura (ITP). For the geeks out there, the new treatment is based on neonatal Fc receptor (FcRn).
The new treatment negates the need for immunoglobulin (Ig), which are antibodies extracted from blood. Ig is something that CSL sells.
MG is a condition where patients suffer abnormal weakness of certain muscles. ITP is a blood disorder characterised by a decrease in the number of platelets in the blood.
New rival treatment not a significant threat
Based on current trial results, Macquarie believes that the new treatments could displace around 6% of CSL’s Ig volumes by 2030.
“However, CSL is currently in Phase 3 trials for Hizentra in the treatment of patients with CLL (and HGG) and DM,” said the broker.
“We estimate approval in these indications could provide volume upside of ~4%, providing an offset to impacts from FcRn antagonists in MG and ITP.”
CLL is chronic lymphocytic leukemia and HGG is high-grade gliomas. DM is Diabetes mellitus.
Additional tailwinds for the CSL share price
The broker also believes there will be an increase diagnosis of conditions where Ig is used as a treatment. This will undoubtedly be a boon for the CSL share price too.
Further, the COVID-19 disruption to CSL’s blood collection in the US is easing and its new plasma collection platform may present upside for the group.
How much is the CSL share price worth?
“For CSL, we also see a new plasma collection platform as potentially improving plasma collection efficiency,” added Macquarie.
“This forms the basis for improved gross margin forecasts for CSL Behring from 2H23+.
“Notwithstanding elevated multiples, we see a favourable EPS growth profile and strong balance sheet as attractive.”
Macquarie’s 12-month price target on the CSL share price is $338 a share.
The post CSL (ASX:CSL) share price is the latest to be upgraded by a top broker appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of August 16th 2021
- Top brokers name 3 ASX shares to buy today
- Investors are buying up ARB (ASX:ARB) shares this month, but the company chair has been selling
- Why are ASX 200 mining shares having such a lousy day?
- ASX 200 (ASX:XJO) midday update: NAB hits 52-week high, CSL upgraded
- Own CSL shares? Here’s what’s in the development pipeline
Motley Fool contributor Brendon Lau owns shares of CSL Ltd. and Macquarie Group Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3C6ayDD